Liraglutide, manufactured by Novo Nordisk, is the active ingredient used in two of the company’s older drugs: Saxenda, a weight loss drug, and Victoza, used to treat diabetes.
In the 56-week study, 82 children with non-monogenic, nonsyndromic obesity were randomly assigned to receive either a once-daily dose of liraglutide or a placebo along with lifestyle interventions. The results showed that the children taking liraglutide saw a 5.6% decrease in BMI on average, whereas children receiving the placebo saw a 1.6% increase in BMI.
Roy Kim, MD, a pediatric endocrinologist at Cleveland Clinic, shared concerns with NBC News regarding the long-term safety of using weight loss drugs for children, especially its potential effects on growth, bone health and the pancreas.
The trial results have led Novo Nordisk to apply for FDA approval to expand liraglutide use in younger children, the report said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
